1 Min Read
Dec 7 (Reuters) - Abiomed Inc
* Abiomed Impella CP receives expanded FDA approval for high-risk percutaneous coronary intervention (PCI) procedures Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.